Relmada Therapeutics, Inc. – NASDAQ:RLMD
Relmada Therapeutics stock price today
$0.593
+0.21
+54.91%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Relmada Therapeutics stock price monthly change
-90.57%
month
Relmada Therapeutics stock price quarterly change
-90.57%
quarter
Relmada Therapeutics stock price yearly change
-90.92%
year
Relmada Therapeutics key metrics
Market Cap | 10.70M |
Enterprise value | N/A |
P/E | -0.48 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.51 |
PEG ratio | -0.01 |
EPS | -3.13 |
Revenue | N/A |
EBITDA | -97.26M |
Income | -94.29M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRelmada Therapeutics stock price history
Relmada Therapeutics stock forecast
Relmada Therapeutics financial statements
| Jun 2023 | 0 | -25.30M | |
|---|---|---|---|
| Sep 2023 | 0 | -22.00M | |
| Dec 2023 | 0 | -25.16M | |
| Mar 2024 | 0 | -21.82M |
| Dec 2023 | 0 | -25.16M | |
|---|---|---|---|
| Mar 2024 | 0 | -21.82M | |
| Oct 2025 | 0 | -37.36M | |
| Dec 2025 | 0 | -36.15M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 122038221 | 10.70M | 8.77% |
|---|---|---|---|
| Sep 2023 | 109148853 | 8.42M | 7.72% |
| Dec 2023 | 97552042 | 12.19M | 12.5% |
| Mar 2024 | 84408164 | 12.36M | 14.65% |
| Jun 2023 | -13.27M | -1.15M | 0 |
|---|---|---|---|
| Sep 2023 | -11.63M | 3.86M | 0 |
| Dec 2023 | -10.24M | 7.74M | -98.46K |
| Mar 2024 | -13.03M | 10.05M | 221.74K |
Relmada Therapeutics alternative data
| Aug 2023 | 14 |
|---|---|
| Sep 2023 | 14 |
| Oct 2023 | 14 |
| Nov 2023 | 14 |
| Dec 2023 | 14 |
| Jan 2024 | 14 |
| Feb 2024 | 14 |
| Mar 2024 | 20 |
| Apr 2024 | 20 |
| May 2024 | 20 |
| Jun 2024 | 20 |
| Jul 2024 | 20 |
Relmada Therapeutics other data
28.40%
-35.36%
of RLMD is owned by hedge funds
52
-55
8.06M
-11.10M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 10000 | 0 |
| Jan 2024 | 171645 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 19 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA (1960) Chief Executive Officer & Director | $900,000 |
Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA (1964) Chief Financial Officer | $685,440 |
Mr. Charles S. Ence CPA, M.B.A. (1965) Chief Accounting & Compliance Officer | $453,750 |
-
What's the price of Relmada Therapeutics stock today?
One share of Relmada Therapeutics stock can currently be purchased for approximately $0.59.
-
When is Relmada Therapeutics's next earnings date?
Unfortunately, Relmada Therapeutics's (RLMD) next earnings date is currently unknown.
-
Does Relmada Therapeutics pay dividends?
No, Relmada Therapeutics does not pay dividends.
-
How much money does Relmada Therapeutics make?
Relmada Therapeutics has a market capitalization of 10.70M.
-
What is Relmada Therapeutics's stock symbol?
Relmada Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RLMD".
-
What is Relmada Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Relmada Therapeutics?
Shares of Relmada Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Relmada Therapeutics's key executives?
Relmada Therapeutics's management team includes the following people:
- Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA Chief Executive Officer & Director(age: 65, pay: $900,000)
- Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA Chief Financial Officer(age: 61, pay: $685,440)
- Mr. Charles S. Ence CPA, M.B.A. Chief Accounting & Compliance Officer(age: 60, pay: $453,750)
-
How many employees does Relmada Therapeutics have?
As Jul 2024, Relmada Therapeutics employs 20 workers.
-
When Relmada Therapeutics went public?
Relmada Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 20 Jun 2014.
-
What is Relmada Therapeutics's official website?
The official website for Relmada Therapeutics is relmada.com.
-
Where are Relmada Therapeutics's headquarters?
Relmada Therapeutics is headquartered at 2222 Ponce de Leon Boulevard, Coral Gables, FL.
-
How can i contact Relmada Therapeutics?
Relmada Therapeutics's mailing address is 2222 Ponce de Leon Boulevard, Coral Gables, FL and company can be reached via phone at +7 866291376.
Relmada Therapeutics company profile:
Relmada Therapeutics, Inc.
relmada.comExchange:
NASDAQ
Full time employees:
20
Industry:
Biotechnology
Sector:
Healthcare
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
2222 Ponce de Leon Boulevard
Coral Gables, FL 33134
Coral Gables, FL 33134
CIK: 0001553643
ISIN: US75955J4022
CUSIP: 75955J402
